Composition, form of production and packaging
Eye drops 1 ml
dexamethasone 1 mg
neomycin 3.5 mg
polymyxin B sulfate 6 thousand units
5 ml - polyethylene bottles with dropper Drop-Teiner (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2008.
Combination drug for topical application in ophthalmology.
Neomycin has a bactericidal effect, disrupting the synthesis of the bacterial cell protein. It is active against Staphylococcus aureus, Corynebacterium diphteriae, Streptococcus viridans, Escherichia coli, Klesiella pneumoniae, Proteus vulgaris, Aerobacter aerogenes, Haemophillus influenzae .
The mechanism of action of polymyxin B is mainly due to blockade of the permeability of the cytoplasmic membrane of bacterial cells. It is active againstPseudomonas aeruginosa, Aerobacter aerogenes, Escherichia coli, Klesiella pneumoniae, Koch-Weeks bacillus.
GCS. Has anti-inflammatory, antiallergic and desensitizing effects. Has an antiexudative effect. Dexamethasone effectively suppresses inflammatory processes.
Combination of SCS with antibiotics allows to reduce the risk of development of the infectious process.
With topical application, systemic absorption is low.
Infections of the eyes and its appendages:
Prevention of postoperative infectious complications.
Locally. With a mild infectious process , 1-2 drops in the conjunctival sac 4-6 times / day.
In acute severe infectious process , 1-2 drops in the conjunctival sac every 60 minutes with a decrease in the frequency of instillations of the drug as the phenomena of inflammation decrease.
Local. Allergic reaction, accompanied by itching and swelling of the eyelids, hyperemia of the conjunctiva. Side effects due to the steroid component: increased intraocular pressure with possible subsequent development of glaucoma, damage to the optic nerve and visual fields (with the use of the drug for more than 10 days, monitoring of intraocular pressure is necessary); posterior subcapsular cataract, slowing down the process of wound healing. Local use of steroids in diseases that cause thinning of the cornea or sclera can lead to their perforation.
Secondary infection. The development of secondary infection is observed after the use of combined preparations containing glucocorticosteroids in combination with antibiotics. With prolonged use of steroids, fungal infections of the cornea may develop. The appearance of non-healing ulcers on the cornea after prolonged treatment with steroid preparations may indicate the development of fungal infestation. Secondary bacterial infection can arise as a consequence of suppression of the protective reaction of the patient's body.
- individual hypersensitivity to the components of the drug;
- viral diseases of the eyes (including keratitis caused by Herpes simplex, chicken pox);
- mycobacterial infection of the eyes;
- tuberculosis diseases of the eyes;
- Acute herpes zoster;
- fungal diseases of the eyes;
- condition after removal of the foreign body of the cornea;
- purulent infection of the mucous membrane of the eye and eyelids caused by microorganisms resistant to the action of neomycin, a purulent corneal ulcer.
Caution is prescribed for glaucoma, cataract.
PREGNANCY AND LACTATION
Sufficient experience in the use of the drug during pregnancy and lactation is not present. It is possible to use the treatment for pregnant women on prescription of the attending physician if the expected curative effect exceeds the risk of development of possible side effects. It is necessary to interrupt the use of the drug for the period of breastfeeding.
APPLICATION FOR CHILDREN
Safety and effectiveness of the drug for children are not established.
The bottle must be closed after each use. Shake the bottle before use.
Interaction with other drugs is not currently known.
In case of use with other local ophthalmic preparations, the interval between their use should be at least 10 minutes.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.